Erik Phelps, the Executive Vice President and Chief Administrative and Legal Officer of Tempus AI , Inc. (NASDAQ:TEM), ...

Andrew Polovin, the Executive Vice President and General Counsel of Tempus AI , Inc. (NASDAQ:TEM), a company currently valued at $10.2 billion, recently executed a stock sale as part of a pre-arranged ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

The new Kids First datasets advance our understanding of how genetics contribute to childhood cancers and congenital disorders, opening new doors for prevention and treatment.

Nancy Pelosi's newest bet saw the purchase of Tempus AI call options — now, a Wall Street analyst has given the stock a new ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide ...

It looks like 2025 will be a revolutionary year for INFINOX. The CFD Broker is prepared to continue its remarkable 2024 with even greater expansion, innovation, and trust-building initiatives. The ...